Drug Profile


Alternative Names: Aripazine; PER 977

Latest Information Update: 06 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Perosphere
  • Class Amides; Coagulants; Piperazines; Small molecules
  • Mechanism of Action Blood coagulation factor modulators; Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Haemorrhage

Most Recent Events

  • 08 May 2017 Perosphere initiates enrolment in a phase II trial for Haemorrhage (In adults, In the elderly, In volunteers) in USA (NCT03172910)
  • 15 Dec 2016 Biomarkers information updated
  • 04 Oct 2016 Phase-II development is ongoing in USA (Perosphere pipeline, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top